Cigarette Reduction Using the Quitbit Digital Lighter and Mobile Application for Smoking Cessation: a Randomized Controlled Trial

Smoking Cessation Clinical Trial

Official title:

Cigarette Reduction Using the Quitbit Digital Lighter and Mobile Application for Smoking Cessation: a Randomized Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02515500
• Other study ID #: 16-18722
• Status: Completed
• Phase: N/A
• Start date: June 2016
• Est. completion date: June 2018

Study information

• Verified date: January 2020
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is designed to evaluate the efficacy of a cigarette reduction intervention using a novel device called the Quitbit, a digital lighter paired with a smartphone mobile application, to enhance self-regulatory techniques for reducing cigarettes smoked per day toward cessation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 124
• Est. completion date: June 2018
• Est. primary completion date: June 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years of age

• cigarette smoker

• wanting to quit in the next 30 days

• preference to quit gradually (vs. abruptly) or having no preference

• access to an iPhone (iOS only)

• completion of a run-in period

Exclusion Criteria:

• no major change in number of cigarettes per day in the past month (+/- 20%)

• no major health diagnoses that could impact study attrition

Related Conditions & MeSH terms

• Smoking Cessation

Intervention

Behavioral:
• Gradual Cessation

• Gradual Cessation w/ Quitbit

Locations

Country	Name	City	State
United States	University of California, San Francisco	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, San Francisco	Quitbit, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Saliva cotinine level		6 Months